The present invention relates to a boron carrying agent for integrated tumor diagnosis and treatment, and a preparation method therefor and use thereof. Provided is a compound represented by formula I: wherein an R group is hydrogen or alkyl. A boron atom connected to the benzene ring may be 10B or natural boron, and at least one fluorine atom in —BF 3- is radiolabeled. The present invention generally relates to the fields of radiopharmaceuticals and nuclear medicine. The compound in the present invention can be used for a drug for integrated diagnosis and treatment in tumor diagnosis and BNCT treatment, and by means of the same chemical structure, a reliable distribution result of a drug in vivo is provided.

The present invention relates to cell radiolabelling agents. The invention provides a method of preparing oxine-containing cell radiolabelling agents, a kit for the preparation of oxine-containing cell radiolabelling agents and a formulation for the preparation of oxine-containing cell radiolabelling agents, in particular .sup.89Zr-oxine cell radiolabelling agents.

The present application provides a compound comprising at least one isotopically labeled nitrogen atom for use in diagnosing a condition or disease in a subject, compositions and kits comprising the compound and methods of using the same.

Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

A polycyclic aromatic derivative compound according to the present invention is employed in an organic layer in a device, thus being able to implement a high-efficiency organic light-emitting device, and thus can be industrially and effectively used in various display devices such as flexible displays, and illumination apparatuses such as monochromatic or white flat illumination and monochromatic or white flexible illumination.

A method for preparing .sup.18F-BPA and an intermediate, by which high-purity .sup.18F-BPA is obtained. The method simplifies the synthesis steps after .sup.18F labeling, and is easy to operate and efficient.

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

A method for evaporatively concentrating a radioactive metal nuclide, including: a first evaporative concentration process in which a radioactive solution formed by dissolving a radioactive metal nuclide in an acidic aqueous solution is heated to evaporate a solvent in the radioactive solution so as to obtain a concentrated liquid containing the radioactive metal nuclide; and a second evaporative concentration process in which a low-boiling organic solvent having a lower boiling point than water is added to the concentrated liquid, and the concentrated liquid is heated to induce azeotropic boiling of the concentrated liquid and the low-boiling organic solvent so as to obtain an evaporative concentrate of the radioactive metal nuclide.

It relates to the medicinal chemistry field, particularly to a process for separating the isomeric compounds comprising a ring-opened thiosuccinimide group and a chiral moiety.

The present disclosure sets forth novel compounds and compositions including heteroaromatic silicon-fluoride-acceptors, which are useful for PET scanning. The present disclosure further includes novel methods of .sup.18F imaging for PET scanning, the methods comprising the preparation of conjugates and bioconjugates of biological ligands of interest with heteroaromatic silicon-fluoride-acceptors. In certain embodiments the invention is practiced in the form of a kit.